RMC-6236 + cetuximab for colorectal or pancreatic cancer (RMC-GI-102_B)

Study Details

Full Title

[RMC-GI-102_B] Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma ? Subprotocol B

Principal Investigator

John
Strickler

Protocol Number

PRO00115669

NCT ID

NCT06445062

Phase

I/II

Enrollment Status

Open to Enrollment